Velpatasvir

{{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = Methyl {(2S)-1-[(2S,5S)-2-(9- {2-[(2S,4S)-1…

Uses your system voice; voice and rate in settings.

≈ 4 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

{{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = Methyl {(2S)-1-[(2S,5S)-2-(9- {2-[(2S,4S)-1- {(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate | image = Velpatasvir.svg | image_class = skin-invert-image | width = 275 | tradename = Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir) | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral (tablets) | bioavailability = | protein_bound = >99.5% | metabolism = Liver (CYP2B6, 2C8, 3A4) | elimination_half-life = 15 hours | excretion = Feces (94%), urine (0.4%) | CAS_number_Ref = | CAS_number = 1377049-84-7 | ATC_prefix = J05 | ATC_suffix = AP55 | ATC_supplemental = (combination with sofosbuvir) (combination with sofosbuvir and voxilaprevir) | PubChem = 67683363 | DrugBank_Ref = | DrugBank = DB11613 | ChemSpiderID = 34501056 | ChEBI_Ref = | ChEBI = 133009 | ChEMBL = | UNII_Ref = | UNII = KCU0C7RS7Z | KEGG = D10806 | C=49 | H=54 | N=8 | O=8 | molecular_weight = | smiles = COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6[nH]c([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1 | StdInChI = 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 | StdInChIKey = FHCUMDQMBHQXKK-CDIODLITSA-N | synonyms = }} Velpatasvir is an NS5A inhibitor (by Gilead) which is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

Side effects

Side effects in studies occurred with similar frequencies as in people treated with placebo.

Interactions

Velpatasvir is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3. It is partly degraded by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. Substances that are transported or inactivated by these proteins, or interfere with them, can interact with velpatasvir.

In studies, this has been found for the HIV combination efavirenz/emtricitabine/tenofovir, which reduces the area under the curve (AUC) of velpatasvir by about 50%, and the CYP3A4 and Pgp inducer rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective. Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with velpatasvir and sofosbuvir (although it is not clear which of the two is responsible for this effect).

Substances that reduce gastric acid, such as antacids, H 2 blockers, and proton pump inhibitors, reduce velpatasvir AUC by 20–40%.

Mechanism of action

The substance blocks NS5A, a protein necessary for hepatitis C virus replication and assembly.

Pharmacokinetics

Velpatasvir reaches highest blood plasma levels three hours after oral intake together with sofosbuvir. Plasma protein binding is over 99.5%. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4.

While monohydroxylated and demethylated metabolites have been identified in human blood plasma and faeces, over 98% of the circulating substance is velpatasvir itself. 94% are excreted via the faeces, and only 0.4% via the urine. Biological half-life is about 15 hours.

See also

Discovery and development of NS5A inhibitors Sofosbuvir/velpatasvir/voxilaprevir, with more information about the drug combination Sofosbuvir/velpatasvir, with more information about the drug combination

Text derived from https://en.wikipedia.org/w/index.php?oldid=1269008786 under CC BY-SA 4.0; modifications have been made.

Words in each sectionInteractionsInteractionsInteractions: 144 words144PharmacokineticsPharmacokineticsPharmacokinetics: 75 words75See alsoSee alsoSee also: 46 words46Side effectsSide effectsSide effects: 14 words14Mechanism of actionMechanism of actionMechanism of action: 14 words14
Words in each section. Measured from the stored article body; sections below the minimum are not plotted.

Provenance

snapshot enwiki-001269008786 · captured 2025-01-12 · ledger · version history

Cite this page as: encyclopegia.org, “Velpatasvir”, snapshot enwiki-001269008786. https://encyclopegia.org/a/velpatasvir

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.